MoneyWorks4Me

The Total revenue for the quarter ended March 2024 of  Rs. 119.73 millions remain, more or less, the same.The Net Loss for the quarter ended March 2024 is Rs. -58.48 millions as compared to Net Loss of Rs. -69.39 millions of corresponding quarter ended March 2023 Operating profit Margin for the quarter ended March 2024 improved to -29.04% as compared to -44.31% of corresponding quarter ended March 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 119.73 114.61 4.47 504.22 521.34 -3.28 504.22 521.34 -3.28
Other Income 2.10 1.93 8.81 4.51 6.20 -27.26 4.51 6.20 -27.26
PBIDT -29.04 -44.31 -34.46 -82.72 -151.59 -45.43 -82.72 -151.59 -45.43
Interest 12.72 10.28 23.74 46.89 29.73 57.72 46.89 29.73 57.72
PBDT -41.76 -54.59 -23.50 -129.61 -181.32 -28.52 -129.61 -181.32 -28.52
Depreciation 16.72 14.80 12.97 67.66 65.59 3.16 67.66 65.59 3.16
PBT -58.48 -69.39 -15.72 -197.27 -246.91 -20.10 -197.27 -246.91 -20.10
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -58.48 -69.39 -15.72 -197.27 -246.91 -20.10 -197.27 -246.91 -20.10
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -24.25 -38.66 -37.26 -16.41 -29.08 -43.58 -16.41 -29.08 -43.58

Krebs Biochem.&Inds Share Price

56.00 3.88 (7.44%)
04-Sep-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.00
Dr. Reddys Labs. 1154.00
Cipla 1385.00
Lupin 2111.00
Zydus Lifesciences 1121.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: